Janssen presents positive results from phase II RSV vaccine trial

The promising phase IIb data comes shortly after the announcement of plans for a phase III trial.

Photo: Shannon Stapleton/Reuters/Ritzau Scanpix

Janssen's vaccine against respiratory syncytial virus, known as RSV, has lived up to the company's expectations in the latest study.

This was already apparent a few days ago, when Janssen informed the market of its intention to begin a phase III trial involving 23,000 patients. Now, the company has followed up on that news with more data from the phase IIb study, which preceded the new phase III.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs